Global Blood Therapeutics reported a GAAP loss of $74.93 million for three months of 2021, up 2.6% from $73.026 million in the prior year. Revenue doubled to $39.043 million from $14.118 million a year earlier.
Global Blood Therapeutics reported a GAAP loss of $74.93 million for three months of 2021, up 2.6% from $73.026 million in the prior year. Revenue doubled to $39.043 million from $14.118 million a year earlier. 
ir.gbt.com
English (US) 